Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Psychiatry indexChapter sections
Purpose and principlesIndications, selection and cautionsAssessment before treatmentTreatment approachRegimens, contraindications and interactionsComplications, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook10 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Medication withdrawal, switching and deprescribing

Psychiatry · UK scope · Sources checked 7 Sept 2026 · Clinical review pending

RapidFull
!
A medicine change can precipitate crisis

Seizures, delirium, severe autonomic disturbance, suicidal intent, mania or rapidly worsening psychosis during withdrawal require urgent assessment rather than simply extending the next review interval.

Action: Assess immediate safety, observations, medication exposure and the change schedule, arrange emergency care where indicated and involve the prescribing specialist before restarting or overlapping high-risk medicines.

Purpose and principles

Plan collaborative psychotropic withdrawal or switching, distinguish withdrawal from relapse and new toxicity, and use medicine-specific tapering and washout rules to avoid preventable destabilisation.

Deprescribing is a planned treatment intervention that seeks to reduce harm or unnecessary exposure while preserving function and psychiatric stability. Reasons may include sustained recovery, lack of benefit, adverse effects, changed physical health, pregnancy planning or the person's informed preference. Begin by reconstructing the actual regimen, including medicines from multiple prescribers, as-required use, alcohol and non-prescribed substances. Clarify whether the aim is a lower dose, complete cessation or a switch to another treatment.

Withdrawal occurs when the nervous system adapts to a reduction in established drug exposure. Physical dependence is not equivalent to addiction, and symptoms should not be dismissed as drug-seeking. An antidepressant may produce withdrawal without craving or compulsive use. Timing helps: symptoms emerging within days of a reduction, especially novel sensory or gastrointestinal symptoms, make withdrawal more likely. Relapse often resembles the person's previous illness and may develop more gradually, but overlap is common and no single timing rule settles every case.

Indications, selection and cautions

Withdrawal pattern

New dizziness, disequilibrium, nausea, electric-shock sensations or vivid dreams follows a dose reduction or missed doses and differs from the original illness.

Relapse pattern

Return of the person's characteristic depressive, manic or psychotic symptoms requires comparison with their previous episodes and the broader clinical course.

Switch-related toxicity

Neuromuscular excitation, autonomic changes or excessive sedation after overlapping medicines suggests an interaction rather than simple withdrawal.

Practical dosing problem

Confusion about tablet strengths, liquid concentrations or which medicine stops on which date can create unintended abrupt cessation or duplicate treatment.

Red flags requiring action

  • Fever, clonus, hyperreflexia and agitation during an antidepressant switch suggests serotonin toxicity and requires urgent cessation assessment and medical treatment.
  • Seizure or delirium after abrupt benzodiazepine withdrawal is a medical emergency, particularly after prolonged high-dose use.
  • New reduced need for sleep, overactivity, disinhibition or psychosis during mood-stabiliser reduction needs prompt psychiatric review.

Assessment before treatment

  1. 01
    Reconciled dose-by-dose historyFirst step
    Why
    Determine actual exposure rather than relying on the written schedule.
    Interpretation and limitations
    Ask about the last doses, missed days and formulation changes; symptoms cannot be interpreted accurately if the exposure timeline is wrong.
  2. 02
    Mental state and safety assessment
    Why
    Identify relapse, self-harm risk, mania or psychosis requiring escalation.
    Interpretation and limitations
    Compare with the person's usual illness signature and include sleep, function, supports and access to medication supplies.
  3. 03
    Physical assessment and targeted tests
    Why
    Exclude medical causes or serious toxicity when symptoms warrant investigation.
    Interpretation and limitations
    Observations, glucose, electrolytes, renal function, ECG or drug levels are selected by the syndrome; a withdrawal label must not prevent ordinary acute assessment.
  4. 04
    Drug-pair interaction and formulation check
    Why
    Choose a safe switching method and a deliverable taper.
    Interpretation and limitations
    Consult a pair-specific SPS guide and current product information, including enzyme effects, long-lived metabolites, modified release and licensed formulation differences.

Treatment approach

01Planned reductionAgree a flexible taperFirst stepThe person and prescriber decide that reducing or stopping a psychotropic is appropriate.+
  1. 1Review benefit, relapse history, previous withdrawal and current supports, agreeing which medicine to address first.
  2. 2Write stepwise reductions proportionate to the current dose and allow adequate time at each step for symptoms to settle.
  3. 3Arrange follow-up and a contingency plan before the first reduction, adjusting the pace according to tolerability and clinical risk.
02Symptoms emergeReassess before pressing aheadNew symptoms appear during a reduction or shortly after stopping.+
  1. 1Check the timeline and assess whether findings fit withdrawal, relapse, a new illness or an interaction.
  2. 2For troublesome withdrawal consider pausing, making a smaller next reduction or returning to the last tolerated dose after clinical review.

Regimens, contraindications and interactions

A necessary washout strategy to reduce hazardous serotonergic overlap from fluoxetine and its long-lived metabolite.

Fluoxetine to an MAOI

Under specialist direction gradually reduce fluoxetine to 20 mg orally daily and stop; wait five to six weeks before starting the selected MAOI at its appropriate initial dose.

Do not cross-taper fluoxetine with an MAOI; the final washout and initiation plan must consider previous dose, duration, interactions and the chosen product.

A relapse-risk reduction strategy for elective cessation, including when another antimanic medicine has already started.

Planned lithium withdrawal in bipolar disorder

Reduce the established oral lithium dose gradually over at least four weeks and preferably up to three months, with the individual decrement set by the specialist plan.

This schedule does not apply to suspected acute toxicity requiring immediate withholding; monitor closely for mania and depression during reduction and for three months after stopping.

Complications, monitoring and follow-up

  • Review after each meaningful dose reduction and before the next step when symptoms are unsettled; the interval should match the medicine's half-life and the person's risk.
  • During antidepressant switching arrange an early review, usually within two weeks and sooner for young adults or heightened suicide risk.
  • For antidepressant withdrawal, paroxetine and venlafaxine often need particular caution because short effective half-lives can produce symptoms after missed doses.
  • Following antipsychotic withdrawal in schizophrenia monitor for relapse for at least two years, with accessible crisis and re-referral routes.
  • Record the agreed final regimen across GP, pharmacy and specialist records so discontinued doses do not reappear through an automatic repeat prescription.

Special situations

Small final doses still matter

The final step from a low dose to zero can produce substantial symptoms, so a taper should not be judged solely by the number of milligrams removed.

Alternate days are usually unhelpful

Skipping days creates fluctuating exposure for many antidepressants; fluoxetine is a specific long-half-life exception in some carefully planned withdrawal schedules.

Withdrawal can be prolonged

Some people need weeks or months for reductions and recovery, and the clinician should acknowledge this variation without promising a universal end date.

One change at a time

Sequential changes usually make symptom attribution easier, although serious toxicity or a specialist transition may justify a coordinated change to several medicines.

Common pitfalls

  1. 01

    Calling every post-reduction symptom relapse and automatically returning to indefinite treatment without considering withdrawal.

  2. 02

    Using the same cross-taper template for an SSRI-to-SSRI switch and an SSRI-to-MAOI switch.

  3. 03

    Crushing a modified-release medicine to obtain a smaller dose without checking whether the formulation permits it.

  4. 04

    Treating a request to pause the taper as non-cooperation instead of reviewing symptoms and circumstances.

  5. 05

    Allowing an old repeat prescription to restart the pre-taper dose after the person has safely reduced.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
PsychiatryOriginal SBA

Symptoms after venlafaxine reduction

An adult in sustained remission develops dizziness, electric-shock sensations and nausea within two days of a substantial venlafaxine reduction. These symptoms were absent during previous depression. What is the best next step?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Psychiatry topics →
Sources and review status7 sources · checked 7 Sept 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.

  • NICE NG215 withdrawal managementCollaborative proportional reduction and withdrawal symptom management.
  • SPS SSRI antidepressant switchesDrug-pair switching rules and fluoxetine washout.
  • SPS antidepressant switching strategiesDirect switch, cross-taper and washout approaches.
  • NICE NG222 stopping antidepressantsWithdrawal, review and formulation considerations.
  • NICE CG185 stopping lithiumElective taper duration and relapse monitoring.
  • NICE CG178 antipsychotic withdrawalGradual withdrawal and two-year relapse surveillance.
  • Royal College of Psychiatrists stopping antidepressantsPatient-centred tapering and alternate-day cautions.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem ·

A good plan specifies the formulation, dose at each stage, review dates and actions if symptoms occur. Proportional reductions become smaller as the dose falls; tablet strengths can make the final stages harder than the first. Liquid preparations or other suitable formulations may help, but concentrations, bioavailability and measuring devices must be checked with pharmacy. Do not assume that crushing a modified-release product or skipping alternate days gives an equivalent smooth reduction.

Switching introduces additional risks: withdrawal from the original medicine, adverse effects from the new one, and interactions during overlap or residual exposure. Cross-tapering can reduce untreated time but is unsafe for some combinations. A direct switch may be reasonable for specified SSRI pairs while being hazardous for an MAOI transition. Long half-life and enzyme inhibition can outlast the last dose, so the absence of tablets in the regimen does not mean the absence of pharmacological effect.

Follow-up should assess symptoms and practical circumstances together. Poor sleep, acute stress, loss of support or physical illness can make a previously tolerable taper difficult. Agree whom to contact and how quickly, particularly when there is a history of severe withdrawal, suicidality or bipolar relapse. A severe symptom may justify returning to a previously tolerated dose after assessment, then attempting a slower reduction. Continuing an agreed lower or original dose can also be reasonable when current risks outweigh the benefit of further reduction.

Key points

  • Establish why treatment is changing, whether the original indication remains active, and what successful reduction would mean to the person.
  • For most psychotropics avoid abrupt cessation unless serious toxicity or another urgent medical circumstance makes rapid withdrawal necessary.
  • Antidepressant reductions should usually be stepwise and proportional to the current dose, with smaller decrements towards the end.
  • Withdrawal may begin soon after a reduction and include dizziness, nausea, electric-shock sensations, vivid dreams and unusual anxiety.
  • A direct switch, cross-taper and taper-then-washout are distinct strategies; choose from the exact drug pair and interaction profile.
  • Fluoxetine has a long-lived active metabolite and requires a five- to six-week washout before an MAOI under specialist advice.
  • A planned lithium stop for bipolar disorder should take at least four weeks and preferably up to three months, even after another antimanic drug starts.
  • A pause in reduction can be a sensible response to symptoms and is not evidence that the person has failed.
  • 3EscalationEscalate severe psychiatric or physical symptoms urgently and revise the continuing treatment plan with the person.
    • 03Antidepressant switchUse the exact medicine-pair strategyA replacement antidepressant is selected because efficacy or tolerability is inadequate.+
    1. 1Identify the required direct switch, cross-taper or taper-and-washout using the original and destination medicines.
    2. 2Check contraindicated overlap, remaining enzyme inhibition and the duration of active metabolites before setting dates.
    3. 3Provide a clear written schedule and early review for withdrawal, adverse effects, serotonin toxicity and change in suicide risk.
    Content changes
    Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom